AllAnalyst Report
Morningstar•February 26, 2021
Morningstar•February 26, 2021Dr. Reddy's Laboratories Limited: Dr. Reddy Reports a Strong Third Quarter, Yet Short of Unreasonable Consensus Expectations
Summary
With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, pharmaceutical services and active ingredients, and proprietary products and other, which make up mos
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Cardinal Health, Inc.Apr 24, 2024 •
CAH
- The Argus Innovation Model PortfolioApr 23, 2024 •
GOOGL, AMAT, ANET, AAPL, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, NVDA, META, SYK, BSX, ORCL, CBOE, PWR, MCK, NOW, ADBE, LYFT, SCHW, MCHP, ISRG, AMZN, CRM, ODFL
- Analyst Report: Cardinal Health, Inc.Apr 23, 2024 •
CAH
- Analyst Report: Wipro LimitedApr 19, 2024 •
WIT
- Technical Assessment: Neutral in the Intermediate-TermApr 19, 2024 •
AA, LLY
Analyst Profile
Soo Romanoff
Equity AnalystTancrede Fulop, CFA, is an equity analyst for Morningstar Holland BV, a wholly owned subsidiary of Morningstar, Inc. He covers European utilities.Before joining Morningstar in early 2017, Fulop worked for Schlumberger Business Consulting as a financial and economist analyst. Previously, he was a senior research associate covering European utilities for Raymond James from 2011 to 2015.Fulop holds a master’s degree in finance from the University Paris II Pantheon-Assas. He also holds the Chartered Financial Analyst® designation.